Good questions Hat'. Pay per Tx sounds messy. We need a return on capital, ie a lot of use, or bad investment. I need a lot more information about outcomes before I can recommend this Tx to patients. Then we need an education program directed at optometrists, because unless it's the second eye, they will be the ones making the Dx and referral for Tx. Some of them are just catching on to vitreolysis, could be a long haul . . .
LP.
Good questions Hat'. Pay per Tx sounds messy. We need a return...
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.005(1.82%) |
Mkt cap ! $61.77M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $108.5K | 410.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 157298 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 471179 | 1 |
View Market Depth
| Last trade - 15.46pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
26.5¢ |
Change
-0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 26.5¢ | 27.0¢ | 25.5¢ | 333518 | ||
| Last updated 15.45pm 03/05/2024 ? | |||||
| EYE (ASX) Chart |